Treatment of venous thromboembolism in cancer patients

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 7, 2007, Pages 707-711

  Petralia, Gloria A ^a   Kakkar, Ajay K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Deep vein thrombosis; Heparin; Low molecular weight heparin; Neoplasms; Pulmonary embolism; Thromboembolism; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; CYCLOPHOSPHAMIDE; DALTEPARIN; ENOXAPARIN; EPIRUBICIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; VINCRISTINE; WARFARIN;

ANTICOAGULATION; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RECURRENCE; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 36348935119     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991539     Document Type: Review

References (27)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Pais 1865;3:654-712
2. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488
3. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. [see comment] J Clin Oncol 2000;18:3078-3083
4. Petralia G, Kakkar AK. Antithrombotic therapy with low molecular weight heparin in cancer patients. Eur J Med Res 2004;9:119-124
5. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):401S-428S
6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;(3 Suppl):188S-203S
7. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
8. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809
9. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188
10. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86:1368-1373
11. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997;89:3236-3242
12. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. [see comment] N Engl J Med 1996;334:677-681
13. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. [see comment] [Erratum appears in N Engl J Med 1997;337:1251] N Engl J Med 1996;334:682-687
14. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. [see comment] N Engl J Med 1992;326:975-982
15. Martins R, Colowick A, al Ewenstein B. Anticoagulation in cancer patients with venous thromboembolic disease. Blood 1997;909(Suppl 1):297A
16. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995;74:1055-1058
17. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. [see comment] Arch Intern Med 2002;162:1729-1735
18. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. [see comment] N Engl J Med 2003;349:146-153
19. Deitcher S, Kessler C, Merli G, Rigas J, Lyons R, Cort S. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period. [abstract] J Thromb Haemost 2003;1(Suppl 1):OC194
20. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. [see comment] Am J Med 1996;100:269-277
21. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-952
22. Kakkar AKZ, Williamson R, Levine M, Low V, Lemoine N. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. Blood Coagul Fibrinolysis 2002;100:148A
23. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948
24. Klerk C, Smorenburg S, Otten J, Büller H. Malignancy and low-molecular weight-heparin therapy: the MALT trial. [abstract] J Thromb Haemost 2003;1(Suppl 1):OC195
25. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129
26. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994;74:38-45
27. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271